Credit Suisse Group upgraded shares of AstraZeneca plc (LON:AZN) from a neutral rating to an outperform rating in a research note issued to investors on Monday, Marketbeat.com reports. Credit Suisse Group currently has GBX 5,800 ($77.07) price target on the biopharmaceutical company’s stock, up from their previous price target of GBX 4,800 ($63.78).

Several other equities research analysts also recently commented on the stock. Citigroup Inc. reaffirmed a buy rating and set a GBX 6,000 ($79.72) price objective on shares of AstraZeneca plc in a report on Thursday, July 13th. Barclays PLC set a GBX 6,300 ($83.71) price objective on shares of AstraZeneca plc and gave the company a buy rating in a report on Wednesday, September 13th. Liberum Capital reaffirmed a buy rating and set a GBX 4,800 ($63.78) price objective on shares of AstraZeneca plc in a report on Tuesday, September 5th. Deutsche Bank AG reaffirmed a buy rating and set a GBX 5,700 ($75.74) price objective on shares of AstraZeneca plc in a report on Friday, June 30th. Finally, Natixis raised shares of AstraZeneca plc from a neutral rating to a buy rating and upped their price objective for the company from GBX 5,000 ($66.44) to GBX 5,738 ($76.24) in a report on Wednesday, September 6th. Three research analysts have rated the stock with a sell rating, seven have assigned a hold rating and twelve have issued a buy rating to the stock. The company currently has an average rating of Hold and a consensus price target of GBX 5,172.64 ($68.73).

Shares of AstraZeneca plc (LON AZN) opened at 5190.00 on Monday. The stock’s 50 day moving average is GBX 4,904.35 and its 200-day moving average is GBX 4,912.64. AstraZeneca plc has a 1-year low of GBX 3,996.00 and a 1-year high of GBX 5,520.00. The firm’s market cap is GBX 65.71 billion.

TRADEMARK VIOLATION NOTICE: “AstraZeneca plc (AZN) Raised to “Outperform” at Credit Suisse Group” was reported by Watch List News and is owned by of Watch List News. If you are reading this piece of content on another website, it was illegally copied and republished in violation of United States and international trademark & copyright laws. The original version of this piece of content can be accessed at https://www.watchlistnews.com/astrazeneca-plc-azn-raised-to-outperform-at-credit-suisse-group/1642276.html.

In other AstraZeneca plc news, insider Nazneen Rahman purchased 39 shares of AstraZeneca plc stock in a transaction on Thursday, July 27th. The shares were acquired at an average cost of GBX 4,370 ($58.07) per share, for a total transaction of £1,704.30 ($2,264.55).

About AstraZeneca plc

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.

Analyst Recommendations for AstraZeneca plc (LON:AZN)

Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with Analyst Ratings Network's FREE daily email newsletter.